PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC12016742::ACT015732

GI

Evidence text

Paper-level observation

B16F10 melanoma‐bearing mice treated with TAAs + αPD‐1 and StCl‐GI_GII + αPD‐1 presented with tumors displaying a significantly reduced frequency of BECs (P = 0.0315 and P = 0.0469, respectively) (Figure 5m).
textConfidence: medium

Assay observation

Activity
Immunomodulatory
Subtype
Antibacterial
Measure
percent_inhibition
Comparator
=
Raw observation
P = 0.0315 vs PBS
Normalized measurement
=0.0315
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
Mus musculus
Assay method
Not reported by source
Sequence
EGSRNQDWL
Standardization
ready simple

Source publication

Off‐The‐Shelf Multivalent Nanoconjugate Cancer Vaccine Rescues Host Immune Response against Melanoma

Advanced Materials · 2025

DOI 10.1002/adma.202417348 PMC12016742
Parent mention

Related peptide identities

PEPDIA-PLP-000563

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.